Pharmaceutical Raw Materials and GMP: How to Ensure Quality and Safety According to Strict Standards

Photo: Toon Lambrechts / Unsplash

The production of pharmaceuticals requires adherence to the strictest quality and safety standards, including Good Manufacturing Practice (GMP). This applies not only to final products but also to all input raw materials – active substances, excipients, and auxiliary substances. For manufacturers and distributors of pharmaceutical raw materials, it is crucial not only to ensure their chemical purity but also proper documentation, storage, and handling. What specific requirements does GMP impose on safety data sheets (SDS), certifications, and control processes? And how do these standards intersect with the legislative requirements of REACH and CLP?

GMP and Pharmaceutical Raw Materials: The Foundation of Quality and Safety

The production and distribution of pharmaceutical raw materials are subject to strict regulations, among which the Good Manufacturing Practice (GMP) system plays a key role. This set of rules ensures that all processes – from raw material procurement through production to storage and transport – meet the highest quality and safety standards. GMP focuses on preventing contamination, ensuring consistency of production batches, and documenting every step, which is essential for protecting the end consumer and complying with legislative requirements.

For suppliers of pharmaceutical raw materials, such as GCG Group, GMP means an obligation to work only with certified suppliers, regularly check the quality of incoming materials, and maintain detailed records of each delivery. This includes, for example, validating the purity of raw materials, monitoring storage conditions (temperature, humidity), or verifying stability during transport. Compliance with GMP is not just a matter of legislation but also a competitive advantage – customers in the pharmaceutical industry demand the transparency and reliability that this system guarantees.

REACH and CLP: Legislative Framework for Chemicals in Pharmaceuticals

Pharmaceutical raw materials, as chemical substances, fall under the REACH Regulation (Registration, Evaluation, Authorisation and Restriction of Chemicals), which governs their registration, evaluation, and potential restrictions in the European Union. REACH requires manufacturers and importers to provide detailed data on the properties of substances, their safe use, and risks to health and the environment. For pharmaceutical raw materials, this means that each substance must be properly registered before being placed on the market if its annual volume exceeds 1 tonne.

Alongside REACH, the CLP Regulation (Classification, Labelling and Packaging) applies, ensuring uniform labelling of chemical substances according to the GHS (Globally Harmonised System). CLP establishes the obligation to classify raw materials based on their hazardous properties (e.g., toxic, corrosive, flammable) and to provide them with appropriate warning symbols, standardised hazard statements (H-phrases), and safety instructions (P-phrases). For pharmaceutical raw materials, it is crucial that this information is available in Safety Data Sheets (SDS) and reflects the latest scientific knowledge.

Photo: Toon Lambrechts / Unsplash

Safety Data Sheets (SDS): An Essential Tool for Risk Management

The Safety Data Sheet (SDS) is a fundamental document for communicating risks associated with pharmaceutical raw materials. It must contain 16 mandatory sections covering substance identification, hazard information, composition, first aid measures, fire-fighting instructions, accidental release measures, storage conditions, physicochemical properties, and ecotoxicological data. The SDS must be prepared in accordance with REACH and CLP regulations and regularly updated in case of classification changes or new scientific findings.

For manufacturers and distributors of pharmaceutical raw materials, the SDS is a key tool for ensuring employee safety, regulatory compliance, and transparent communication with customers. For example, the storage section must specify exact temperature limits (e.g., 15–25 °C) or requirements for separate storage of incompatible substances. The SDS also serves as a basis for employee training and the preparation of internal safety procedures, which is particularly important when handling highly potent or sensitive pharmaceutical raw materials.

Certification and Audit: How to Demonstrate Compliance with Standards

Demonstrating compliance with GMP and other standards requires regular audits and certifications. Suppliers of pharmaceutical raw materials must undergo internal and external inspections to verify adherence to processes, documentation quality, and safety measures. External audits are conducted by independent certification bodies or customers themselves to ensure that the supplier meets their specific requirements. The result of a successful audit is a certificate confirming compliance with GMP or other relevant standards.

In addition to GMP, other certifications may also be required, such as ISO for quality management systems or specific pharmaceutical standards like ICH Q7 (for active pharmaceutical ingredients). For distributors, it is crucial to have an established supply chain tracking system that includes regular quality checks of raw materials, supplier validation, and documentation of the origin of each batch. Transparency and the ability to demonstrate compliance with standards are essential for pharmaceutical customers – without them, it is impossible to enter the market with highly regulated products.

Photo: TECNIC Bioprocess Solutions / Unsplash

Process Validation and Documentation: The Key to Repeatable Raw Material Quality

Validation of manufacturing and control processes is a fundamental prerequisite for ensuring consistent quality of pharmaceutical raw materials. According to Good Manufacturing Practice (GMP) principles, every step in raw material processing – from receipt to dispatch – must undergo systematic verification. This includes not only technological parameters (temperature, pressure, mixing time) but also purity criteria, microbiological limits, and stability during storage. Validation is carried out using standard test methods, and the results are documented in protocols that serve as proof of process reproducibility.

An important part of validation is also risk assessment using methodologies such as HACCP or FMEA, which identify potential sources of contamination or deviations. For example, for moisture-sensitive raw materials, it is necessary to validate drying and packaging conditions to prevent degradation of active substances. Documentation must be maintained in accordance with GMP requirements and be readily available for inspections by regulatory authorities, such as the State Institute for Drug Control (SÚKL) or the European Medicines Agency (EMA).

Traceability and Supply Chain Management: From Supplier to Final Product

Traceability of pharmaceutical raw materials is essential for rapid response in the event of quality deviations or safety incidents. Each batch of raw material must be assigned a unique identification number, enabling the tracking of its origin, processing conditions, and distribution paths. This system, known as the "chain of custody," is required not only by GMP but also by the REACH regulation, which emphasizes transparency in the supply chain.

Effective supply chain management relies on collaboration with certified suppliers who meet GMP and other relevant standards. Before finalizing a contract, supplier audits should be conducted, focusing on the inspection of manufacturing processes, storage conditions, and quality management systems. It is also important to verify whether the supplier provides complete safety documentation (SDS) and certificates of conformity confirming that the raw material complies with pharmaceutical specifications.

Staff Training and Quality Culture: The Human Factor in GMP

Compliance with GMP standards depends not only on technological processes but also on qualified and well-trained personnel. Employees handling pharmaceutical raw materials must undergo regular training focused on hygiene, proper handling of raw materials, risk identification, and procedures in emergency situations. Training should also include familiarization with legislative requirements, such as REACH and CLP regulations, and the company’s internal standards.

A quality culture within an organization is built through a systematic approach to education and motivating employees to actively participate in process improvement. For example, implementing a system for reporting deviations or suggestions for improvement can help prevent errors and increase efficiency. It is also important to regularly evaluate the effectiveness of training through tests or practical demonstrations to ensure that staff can apply the acquired knowledge in everyday practice.

Do You Need Raw Materials Meeting GMP Standards?

GCG Group supplies pharmaceutical raw materials with complete documentation, including Safety Data Sheets (SDS) and quality certificates. Our experts will advise you on selecting raw materials and ensuring compliance with GMP and other legislative requirements. Contact us – or browse our catalogue of over 1,300 products right away.